PDA

View Full Version : PubMed - TRT


Pages : 1 [2] 3
  1. Identification of anabolic selective androgen receptor modulators with reduced activi
  2. [Testosterone replacement therapy for prostate cancer.]
  3. Testosterone replacement therapy improves insulin sensitivity and decreases high sens
  4. Effect of sex hormone treatment on circulating adiponectin and subforms in Turner and
  5. The effects of testosterone on risk factors for, and the mediators of, the atheroscle
  6. [Testosterone replacement : Application and surveillance.]
  7. Metabolic and Endocrine Factors in Mild Cognitive Impairment.
  8. 49,XXXXY syndrome with autoimmune diabetes and ocular manifestations.
  9. Is intracytoplasmic sperm injection essential for the treatment of hypogonadotrophic
  10. [Bone and Men's Health. Late-onset hypogonadism in males and male menopause (andropau
  11. Factors influencing time course of pain after depot oil intramuscular injection of te
  12. Short term testosterone replacement therapy improves libido and body composition.
  13. [Prostate carcinoma and testosterone: risks and controversies.]
  14. [Testosterone deficiency in elderly men]
  15. The role of RXFP2 in mediating androgen-induced inguinoscrotal testis descent in lute
  16. Testosterone and the aging male: To treat or not to treat?
  17. Gonadal hormones modulate the potency of the disruptive effects of donepezil in male
  18. Testosterone treatment in elderly men.
  19. Testosterone is essential for alpha(2)-adrenoceptor-induced antinociception in the tr
  20. Quality of life, self-esteem, fatigue, and sexual function in young men after cancer:
  21. Unusual endocrine and somatic phenotypic abnormalities in a 14-year-old boy with clas
  22. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment.
  23. Gender differences in the cardiovascular effects of sex hormones.
  24. Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects
  25. Efficacy and safety of two different testosterone undecanoate formulations in hypogon
  26. Importance of hypogonadism and testosterone replacement therapy in current urologic p
  27. ANE syndrome caused by mutated RBM28 gene: a novel etiology of combined pituitary hor
  28. Men behaving madly: testosterone replacement therapy.
  29. Association of renal damage and oxidative stress in a rat model of metabolic syndrome
  30. Testosterone supplementation therapy as a treatment of hypogonadism.
  31. Osteoporosis in Klinefelter's syndrome.
  32. Klinefelter's Syndrome and sexual function.
  33. Testosterone, tissue factor inhibition and vascular aging.
  34. Endogenous plasma estradiol in healthy men is positively correlated with cerebral cor
  35. [Bone and Men's Health. Testosterone and lifestyle disease]
  36. Editorial comment on: A randomized phase 1 study of testosterone replacement for pati
  37. Symptomatic response rates to testosterone therapy and the likelihood of completing 1
  38. Baseline Serum Testosterone in Men Treated with Androgen Deprivation Therapy and Radi
  39. [Testosterone and infertility]
  40. Testosterone and heart failure.
  41. Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism.
  42. Testosterone Deficiency and Exercise Intolerance in Heart Failure: Treatment Implicat
  43. Ten reasons to be happy about hormone replacement therapy: a guide for patients.
  44. Therapeutic options for postmenopausal female sexual dysfunction.
  45. Effects on lipoprotein particles of long-term dehydroepiandrosterone in elderly men a
  46. Tall stature without growth hormone: four male patients with aromatase deficiency.
  47. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study.
  48. Achievement of fertility in an infertile man with resistant macroprolactinoma using h
  49. Replacement with GABAergic steroid precursors restores the acute ethanol withdrawal p
  50. [Secondary Osteoporosis UPDATE. Treatment of male osteoporosis. - Testosterone replac
  51. Hormone treatment and muscle anabolism during aging: Androgens.
  52. Androgens and menopause.
  53. Contribution of androgen receptor sensitivity to the relation between testosterone an
  54. Late-life onset hypogonadism: a review.
  55. Sarcopenia.
  56. TRT- Compunded Cream help
  57. Lab results and historical data need some ideas
  58. Implanted estrogen pellets associated with hypertriglyceridemia, biliary dyskinesia a
  59. Cardiovascular effect of testosterone replacement therapy in aging male.
  60. The benefit and risk of testosterone replacement therapy in older men: effects on lip
  61. Erectile dysfunction in aging male.
  62. Clinical and laboratoristic strategy in late onset hypogonadism.
  63. Inadvertent castration.
  64. Protection against vanadium-induced testicular toxicity by testosterone propionate in
  65. Obesity: modern man's fertility nemesis.
  66. Testosterone for 'late-onset hypogonadism' in men?
  67. Reproductive hormones and obesity: 9 years of observation from the Study of Women's H
  68. Adrenal hypoplasia congenita - an uncommon reason of primary adrenal insufficiency.
  69. Male hypogonadism associated with advanced cancer: a systematic review.
  70. Severe osteoporosis with multiple vertebral fractures after gender reassignment thera
  71. Effects of testosterone and estrogen replacement on memory function.
  72. Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP1
  73. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 t
  74. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance
  75. Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypot
  76. Guidelines for testosterone therapy for men: how to avoid a mad (t)ea party by gettin
  77. Effects of Testosterone on Skeletal Muscle Architecture in Intermediate-Frail and Fra
  78. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult mal
  79. [Possibilities of testosterone in complex therapy of patients with dilated cardiomyop
  80. Testosterone depletion by castration may protect mice from heat-induced multiple orga
  81. Evaluation of late-onset hypogonadism (andropause) treatment using three different fo
  82. [Gonadotrophic axis dysfunction in men with HIV-infection/aids]
  83. Testosterone undecanoate in the treatment of male hypogonadism.
  84. Androgens and cardiovascular disease.
  85. Testosterone deficiency. Common in midlife and beyond.
  86. Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated
  87. Male menopause: is it a real clinical syndrome?
  88. Late-onset male hypogonadism and testosterone replacement therapy in primary care.
  89. Androgen Replacement Therapy in Late-Onset Hypogonadism: Current Concepts and Controv
  90. The role of testosterone in erectile dysfunction.
  91. Is Hypoandrogenemia a Component of Metabolic Syndrome in Males?
  92. Impact of experimental diabetes and insulin replacement on epididymal secretory produ
  93. Iatrogenic Osteoporosis, Bilateral hip Osteonecrosis, and Secondary Adrenal Suppressi
  94. Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.
  95. Skin and brain age together: The role of hormones in the ageing process.
  96. Multiple lytic lesions in multiple myeloma.
  97. Effects of combined hormone replacement therapy or its effective agents on the IGF-1
  98. Effects of transdermal testosterone on bone and muscle in older men with low bioavail
  99. Transdermal menopausal hormone therapy: delivery through skin changes the rules.
  100. Long-Term Effects of Dimethandrolone 17{beta}-Undecanoate (DMAU) and 11{beta}-Methyl-
  101. Testosterone replacement therapy by testosterone ointment relieves lower urinary trac
  102. Reproductive endocrinology: Testosterone-replacement therapy in older men with limite
  103. Prevention of coronary artery disease in men: Male hormone, female hormone, or both?
  104. Testosterone and Metabolic Syndrome: A Meta-Analysis Study.
  105. [Climacteric in men. When is hormone replacement of value?]
  106. Hypertrophic cardiomyopathy in a patient of Klinefelter syndrome--a rare association.
  107. Effects of Substitutive Therapy on Right Ventricular Systolic and Diastolic Functions
  108. International web survey shows high prevalence of symptomatic testosterone deficiency
  109. Androgen Replacement Therapy After Prostate Cancer Treatment.
  110. Primary Hypogonadism: 46, XX SRY-Positive Male Syndrome in the Setting of Scleroderma
  111. A sex-specific role for androgens in angiogenesis.
  112. Promising research for advanced prostate cancer.
  113. Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnost
  114. Testosterone therapy in women with androgen deficiency: Its time has come.
  115. Focusing on the influence of testosterone on leptin and resistin in male hypogonads:
  116. Testosterone supplementation and prostate cancer, controversies still exist.
  117. Androgen deficiency and therapy in women.
  118. What is the optimal therapy for young males with hypogonadotropic hypogonadism?
  119. Why Is Androgen Replacement in Males Controversial?
  120. REVIEW ARTICLE: Effects of testosterone on Type 2 diabetes and components of the meta
  121. Androgen therapy in hypogonadal adolescent males.
  122. Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen depr
  123. LH and non-SHBG testosterone and estradiol levels during testosterone replacement of
  124. Klinefelter syndrome presenting as behavioral problems in a young adult.
  125. Low serum testosterone and increased mortality in men with coronary heart disease.
  126. Type 2 diabetes mellitus and testosterone: a meta-analysis study.
  127. Testosterone and breast cancer.
  128. Voluntary running, skeletal muscle gene expression and signaling inversely regulated
  129. Rhabdomyolysis associated with phentermine.
  130. [The influence of testosterone on cardiovascular disease in men].
  131. Effects of testosterone administration on nocturnal cortisol secretion in healthy old
  132. Testosterone Therapy: Treatment of Metabolic Disturbances in Heart Failure.
  133. Precocious Puberty Secondary to Topical Testosterone Transfer: A Case Report.
  134. Clinical Inquiries: How should we monitor men receiving testosterone replacement ther
  135. Clinical efficacy of Japanese traditional herbal medicine (Kampo) in patients with la
  136. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus
  137. Testosterone deficiency: a risk factor for cardiovascular disease?
  138. Isoflurane preconditioning neuroprotection in experimental focal stroke is androgen-d
  139. [Therapy of erectile dysfunction after radical prostatectomy].
  140. [Sexual function rehabilitation of men with pituitary tumors].
  141. [Does national health insurance pay for testosterone substitution? In confirmed testo
  142. Importance of hypogonadism and testosterone replacement therapy in current urologic p
  143. Androgen replacement therapy contributes to improving lower urinary tract symptoms in
  144. Racial differences in hypogonadal improvement and prostate-specific antigen levels in
  145. Commentary: Testosterone and the metabolic syndrome: cause or consequence?
  146. Evidence that androgens modulate human thymic T cell output.
  147. Effects of dehydroepiandrosterone supplementation on cognitive function and activitie
  148. Assessment of possible effects for testosterone replacement therapy in men with sympt
  149. Interaction between Testosterone and Growth Hormone on Whole-Body Protein Anabolism O
  150. SHBG, Sex Hormones, and Inflammatory Markers in Older Women.
  151. A case of marinesco-sjögren syndrome: MRI observations of skeletal muscles, bone meta
  152. Panhypopituitarism secondary to a macroprolactinoma presenting with pancytopenia. A c
  153. Why do we need a trial on the effects of testosterone therapy in older men?
  154. Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or
  155. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hyp
  156. Testosterone replacement therapy: take an informed, individualized approach.
  157. 17{beta}-hydroxyestra-4,9,11-trien-3-one (Trenbolone) Exhibits Tissue Selective Anabo
  158. Bone Mass in Subjects with Klinefelter Syndrome: Role of Testosterone Levels and Andr
  159. Androgen deficiency in the aging man.
  160. Testosterone Deficiency as a Risk Factor for Cardiovascular Disease.
  161. Use of endocrine hormones for treating depression.
  162. Intranasal administration of testosterone increased immobile-sniffing, exploratory be
  163. Testosterone treatment of older men--why are controversies created?
  164. Low-dose testosterone treatment decreases oxidative damage in TM3 Leydig cells.
  165. Self-reported psychological distress associated with steroid therapy for HIV.
  166. Testosterone deficiency and treatment in older men: definition, treatment, pitfalls.
  167. Considerations for androgen therapy in children and adolescents with Klinefelter synd
  168. Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 st
  169. Testosterone and coronary artery disease in men.
  170. Metabolic syndrome and the effect of testosterone treatment in young men with congeni
  171. Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patient
  172. Association between venous leg ulcers and sex chromosome anomalies in men.
  173. [38 year-old patient with suspected congenital hormonal dysfunction].
  174. Use of Testosterone Replacement Therapy in Patients with Prostate Cancer.
  175. Selectivity and potency of the retroprogesterone dydrogesterone in vitro.
  176. Bioavailability of testosterone enanthate dependent on genetic variation in the phosp
  177. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syn
  178. Androgen Deficiency in Heart Failure.
  179. Testosterone, cardiovascular disease and the metabolic syndrome.
  180. Effect of thyroid hormone replacement therapy on ovarian volume and androgen hormones
  181. Slipped capital femoral epiphysis in an adult with panhypopituitarism.
  182. Estrogen enhances neurogenesis and behavioral recovery after stroke.
  183. Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal
  184. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial c
  185. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically
  186. Myelodysplastic syndrome treated effectively with testosterone enanthate.
  187. Gender-specific asthma treatment.
  188. Recent topics related to testosterone deficiency syndrome in Japan.
  189. Bioidentical hormones: an evidence-based review for primary care providers.
  190. Hypogonadism predisposes males to the development of behavioural and neuroplastic dep
  191. Predictors of pilosebaceous unit responsiveness to testosterone therapy in patients w
  192. Hormonal therapy in the senescence: Prostatic microenvironment structure and adhesion
  193. Efficacy and Safety Study of 1.62% Testosterone Gel for the Treatment of Hypogonadal
  194. Male late-onset hypogonadism: pathogenesis, diagnosis and treatment.
  195. Varying perceived social threat modulates pain behavior in male mice.
  196. Evidence-Based Medicine Update on Testosterone Replacement Therapy (TRT) in Male Hypo
  197. Effects of unintentional exposure of children to compounded transdermal sex hormone t
  198. Effects of Risedronate and Low-Dose Transdermal Testosterone on Bone Mineral Density
  199. Erectile dysfunction and hypogonadism (low testosterone).
  200. Hormonal therapy with estradiol and testosterone implants: bone protection?
  201. Testosterone replacement therapy and cardiovascular risk factors modification.
  202. Neuroanatomical Phenotype of Klinefelter Syndrome in Childhood: A Voxel-Based Morphom
  203. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalizat
  204. Transdermal estradiol and testosterone transfer in man: existence, models, and strate
  205. Late-onset hypogonadism.
  206. Symptomatic change in Japanese hypogonadal patients several years after androgen repl
  207. Baseline Data From the TRiUS Registry: Symptoms and Comorbidities of Testosterone Def
  208. Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea
  209. Dutasteride Reduces Prostate Size and Prostate Specific Antigen in Older Hypogonadal
  210. Sexual desire in female-to-male transsexual persons: exploration of the role of testo
  211. Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P4
  212. Testosterone and cardiovascular disease: an old idea with modern clinical implication
  213. Change in cytokine levels after administration of saikokaryuukotsuboreito or testoste
  214. Gonadal hormones and cognitive aging: a midlife perspective.
  215. Hypoactive Sexual Desire Disorder and current pharmacotherapeutic options in women.
  216. The endocrine effects of long-term oral opioid therapy: a case report and review of t
  217. An old emperor finds new clothing: rejuvenation in our time.
  218. [Testosterone replacement therapy for androgen deficiency syndrome].
  219. Testosterone is involved in mediating the effects of prenatal stress in male guinea p
  220. Testosterone deficiency and risk factors in the metabolic syndrome: implications for
  221. Testosterone deficiency in men: whom to evaluate, what to measure, and how to treat.
  222. Differing levels of testosterone and the prostate: a physiological interplay.
  223. Synchronous bilateral seminoma.
  224. A case of Klinefelter syndrome with aplastic anemia.
  225. Pituitary choriocarcinoma in an adolescent male: Tumor-derived CG and GH delay diagno
  226. Osteoporosis in men: a review of endogenous sex hormones and testosterone replacement
  227. Testosterone replacement therapy in males with erectile dysfunction.
  228. Sex hormones and gene expression signatures in peripheral blood from postmenopausal w
  229. Efficacy and safety of the 2% formulation of testosterone topical solution applied to
  230. Update in Testosterone Therapy for Men (CME).
  231. Myths and truths of growth hormone and testosterone therapy in heart failure.
  232. Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for
  233. A Small-Scale Clinical Trial to Determine the Safety and Efficacy of Testosterone Rep
  234. Hypogonadotropic hypogonadism due to GnRH receptor mutation in a sibling.
  235. Hypogonadism and Metabolic Syndrome.
  236. Testosterone replacement effectively inhibits the development of experimental autoimm
  237. The struggle for male hormonal contraception.
  238. Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats.
  239. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic
  240. Correction of steroidopenia as a new method of hypercholesterolemia treatment.
  241. Onset of effects of testosterone treatment and time span until maximum effects are ac
  242. Reversible testosterone-induced azoospermia in a 45-year-old man attending an inferti
  243. Chronic anemia as first clinical manifestation of a prolactin-secreting pituitary mac
  244. Hypogonadism, ADAM, and hormone replacement.
  245. Changes in Prostate Specific Antigen in Hypogonadal Men After 12 Months of Testostero
  246. Genetic and environmental predictors, endogenous hormones and growth factors and risk
  247. Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects
  248. Influence of sex and hormone status on circulating natriuretic peptides.
  249. [Testosterone substitution therapy in prostate cancer].
  250. Hormonal management of the female-to-male transgender patient.